Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)

Salvatore Maria Corsello, Roberto Salvatori, Agnese Barnabei, Liana De Vecchis, Paolo Marchetti, Francesco Torino

Risultato della ricerca: Contributo in rivistaArticolo in rivista

11 Citazioni (Scopus)

Abstract

With the expanding use of ipilimumab, oncologists are not only faced with most common side effects, such as diarrhea and rush, but also with unusual adverse events, such as certain endocrinopathies. These include hypophysitis (0–17 %), thyroid disease or abnormalities in thyroid function tests (0–2 %), and occasionally primary adrenal insufficiency
Lingua originaleEnglish
pagine (da-a)489-490
Numero di pagine2
RivistaCancer Chemotherapy and Pharmacology
Volume72
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • Adrenal Cortex Hormones
  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Endocrine System Diseases
  • Humans
  • Hypopituitarism
  • Methylprednisolone
  • Neoplasms
  • Prednisone
  • Thyroid Diseases

Fingerprint Entra nei temi di ricerca di 'Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)'. Insieme formano una fingerprint unica.

Cita questo